Neurizon Therapeutics falls after US FDA denies fast track designation request

Neurizon Therapeutics

01/01/2026 23:40

** Shares of Australia's Neurizon Therapeutics NUZ.AX fall as much as 5.9% to A$0.08, their lowest level since November 23, 2023

** Marks steepest intraday pct fall since December 23

** Biotech company says the U.S. Food and Drug Administration denies its request for Fast Track Designation

** Request was for its investigational new treatment for Amyotrophic Lateral Sclerosis, NUZ-001

 (Reporting by Anjali Singh in Bengaluru)

 ((anjali.singh2@thomsonreuters.com;))